publication date: May. 2, 2014


CL40-18a1.html

NCI officials said they plan to hold a series of meetings with clinical trials group chairs and group financial officers in order to fine-tune the new National Clinical Trials Network.

“We are in the midst of one-on-one meetings with the group chairs and their financial people and their statistical leadership, [meeting] group-by-group [to] look at the numbers as they exist, and try to understand from both sides what that research budget will support and what it won’t support,” said James Doroshow, director of the NCI Division of Cancer Treatment and Diagnosis.

“Without seeing, from the group perspective, what the resources can and can’t support, it’s hard to know from a system-wide perspective how we will move forward.”

In a telephone conference the institute convened to respond to concern from advocates, Doroshow said, in effect, that the budgets sent to the groups recently didn’t represent fait accompli, and that flexibility was an option.

The May 1 call was organized in response to detailed questions submitted to the institute by an ad hoc group of patient advocates who have been involved in clinical trials, mostly as advisors to NCI and the clinical trials groups.

These advocates aren’t members of groups that have large constituencies focused on Washington and Bethesda. Rather they are people who review clinical trials protocols and provide practical advice about the manner in which specific trials and proposed policies would affect clinical trials.

“We have a really big stake in this,” said Michael Katz, the … Continue reading 40-18 NCTN’s Facade

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.